How to Get Dayvigo (Lemborexant) in Vermont

What Is Dayvigo and Why Doctors in Vermont Prescribe It

Dayvigo is the brand name for lemborexant, a dual orexin receptor antagonist approved by the FDA on December 20, 2019 for treatment of insomnia characterized by difficulties with sleep onset or maintenance in adults 1. Unlike benzodiazepines or Z-drugs such as zolpidem, lemborexant does not suppress the central nervous system broadly. Instead, it blocks orexin OX1 and OX2 receptors, the same receptors that drive wakefulness, allowing the brain's natural sleep pressure to take over 2.

Vermont clinicians have adopted lemborexant at a growing rate since 2020, partly because of its favorable next-morning driving data. SUNRISE-2, a 12-month randomized controlled trial (N=949), showed that lemborexant 5 mg and 10 mg produced statistically significant improvements in subjective sleep onset latency versus placebo at month 1 and maintained those improvements through month 12 (P<0.0001 for both doses at month 6) 3. The key SUNRISE-1 trial (N=1,006, published in JAMA Network Open 2019) demonstrated that lemborexant 5 mg and 10 mg significantly reduced latency to persistent sleep compared with placebo and with zolpidem tartrate extended-release 6.25 mg as an active comparator 2. Mean wake after sleep onset at night 1 dropped by 42.2 minutes with lemborexant 10 mg versus 27.8 minutes with zolpidem ER 2.

The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline on pharmacologic treatment of chronic insomnia disorder recommends dual orexin receptor antagonists, including lemborexant, as first-line agents based on moderate-to-high quality evidence 4. Vermont prescribers are expected to follow or at least document departure from these AASM standards when selecting a sleep aid.

How Vermont Prescribing Rules Apply to Dayvigo

Lemborexant is a Schedule IV controlled substance under federal law, and Vermont mirrors federal scheduling without adding state-specific restrictions 5. Vermont licensed physicians (MD, DO), advanced practice registered nurses (APRNs) with prescriptive authority, and physician assistants (PAs) with a collaborative agreement may all prescribe Schedule IV medications, including Dayvigo.

APRNs in Vermont hold independent prescriptive authority once they complete 2 to 400 hours of supervised practice and hold a valid DEA registration. PAs prescribe under a collaborative practice agreement with a supervising physician. Both clinician types can initiate a lemborexant prescription without a physician co-signature, as long as a valid Vermont DEA number is on file.

Telehealth prescribing of Schedule IV substances in Vermont is permitted provided the prescriber has conducted at least one real-time audio-video interaction with the patient and has documented a valid clinical relationship. The Ryan Haight Online Pharmacy Consumer Protection Act requires a DEA registration in the state where the patient is located. For Vermont patients, that means any online prescriber must hold an active Vermont DEA number 6. HealthRX clinicians who see Vermont patients hold Vermont-specific DEA registrations and can prescribe lemborexant through a compliant telehealth visit.

Step-by-Step: How to Get a Dayvigo Prescription in Vermont

Getting a Dayvigo prescription in Vermont follows a predictable sequence regardless of whether you use an in-person office or a telehealth platform.

Step 1. Book a clinical visit. Schedule either an in-person appointment with a Vermont sleep specialist or primary care physician, or a telehealth video visit with a Vermont-licensed provider. The visit typically lasts 20 to 30 minutes. Bring a list of current medications because several drugs (CYP3A inhibitors such as clarithromycin, CYP3A inducers such as rifampin) interact meaningfully with lemborexant's metabolism 1.

Step 2. Complete the sleep history intake. Your clinician will ask about sleep onset latency, wake after sleep onset, total sleep time, sleep hygiene, and prior treatments. Many Vermont telehealth platforms send a validated questionnaire such as the Insomnia Severity Index (ISI) or Pittsburgh Sleep Quality Index (PSQI) before the visit 7.

Step 3. Discuss contraindications and drug interactions. Lemborexant is contraindicated in patients with narcolepsy. It carries a Boxed Warning for complex sleep behaviors (sleep-walking, sleep-driving). Discuss CNS depressant co-use, including alcohol and opioids, because additive sedation is a documented risk 1.

Step 4. Receive the electronic prescription. Vermont participates in PDMP (Prescription Drug Monitoring Program) reporting. Prescribers check the VPMS (Vermont Prescription Monitoring System) before issuing any Schedule IV prescription. Electronic prescriptions for controlled substances (EPCS) are the standard in Vermont.

Step 5. Fill the prescription at a Vermont pharmacy. Chain pharmacies (CVS, Rite Aid, Hannaford, Kinney Drugs), independent Vermont pharmacies, and licensed 503A compounding pharmacies can all dispense lemborexant. Mail-order pharmacies licensed in Vermont can ship to your address.

Step 6. Handle prior authorization if using insurance. Most commercial plans and Vermont Medicaid require a PA. Your prescriber's office submits the PA form; approval typically takes 1 to 5 business days.

What Labs Are Needed Before Starting Dayvigo in Vermont

No mandatory laboratory workup is required by the FDA label before starting lemborexant 1. Dayvigo does not require a CBC, metabolic panel, or polysomnogram as a prerequisite. Vermont clinicians do, however, order targeted tests in specific clinical scenarios.

Liver function tests (LFTs) are recommended before prescribing in patients with suspected moderate to severe hepatic impairment. The FDA label states that lemborexant is not recommended in severe hepatic impairment (Child-Pugh C) and should be used with caution in moderate impairment (Child-Pugh B), with a maximum dose of 5 mg 1.

A thyroid-stimulating hormone (TSH) panel may be ordered if secondary causes of insomnia are suspected. Undiagnosed hyperthyroidism can mimic primary insomnia, and treating the underlying cause removes the need for a sleep aid entirely 8.

Polysomnography or a home sleep apnea test (HSAT) is not required by the label, but Vermont sleep specialists may order one when obstructive sleep apnea is on the differential. OSA-driven insomnia generally responds better to CPAP than to a DORA, and prescribing lemborexant without ruling out moderate-to-severe OSA may mask a life-threatening condition 9.

Pregnancy testing is not formally required by the label but is standard practice at many Vermont clinics before initiating any Schedule IV controlled substance in patients of childbearing age.

Vermont Medicaid Prior Authorization for Dayvigo

Vermont Medicaid (Green Mountain Care) covers Dayvigo under its Preferred Drug List with prior authorization. The PA process requires documentation of three core elements.

First, the prescriber must confirm a diagnosis of chronic insomnia disorder (ICD-10: G47.00) supported by clinical notes showing symptoms persisting for at least 3 months and occurring at least 3 nights per week. The DSM-5-TR definition of insomnia disorder requires this minimum duration and frequency 10.

Second, the prescriber must document that at least one first-line behavioral intervention has been offered. Vermont Medicaid generally accepts a documented referral to cognitive behavioral therapy for insomnia (CBT-I) or a patient refusal note. The AASM classifies CBT-I as the first-line treatment for chronic insomnia before any pharmacotherapy 4.

Third, for most Vermont Medicaid PA forms, the prescriber must document that at least one generic hypnotic has been trialed or is contraindicated. Zolpidem immediate-release is available generically at low cost. If a patient experienced adverse effects such as complex sleep behaviors or residual sedation on zolpidem, documenting that failure strengthens the PA request. SUNRISE-1 data showing lemborexant's superior next-day driving performance compared with zolpidem ER may be appended as clinical justification 2.

Commercial insurance PA requirements in Vermont vary by plan. Blue Cross Blue Shield of Vermont, MVP Health Care, and Cigna all carry lemborexant on their formularies but require step therapy through at least one generic hypnotic first. Your prescriber's office can submit PA paperwork electronically through CoverMyMeds or directly through the insurer's provider portal.

Telehealth Options for Dayvigo in Vermont

Vermont enacted telehealth parity legislation (18 V.S.A. § 9361) that requires insurers to reimburse telehealth services at parity with in-person visits when the services are clinically appropriate. This means a telehealth visit for insomnia evaluation and Dayvigo management is reimbursable by most Vermont commercial plans and by Green Mountain Care 11.

Several national telehealth platforms hold Vermont prescriber licenses, but patients should confirm that the specific clinician assigned to their visit holds a Vermont DEA number before booking. Platforms that use a single national DEA registration (not state-specific) cannot legally prescribe Schedule IV substances in Vermont.

HealthRX clinicians complete a 20-to-30-minute synchronous video visit with Vermont patients, review the VPMS database in real time, and send an EPCS directly to the patient's Vermont pharmacy of choice. Refills for Schedule IV medications in Vermont may not exceed a 30-day supply per prescription. Patients requiring ongoing lemborexant therapy schedule follow-up visits at 30-day or 90-day intervals.

Audio-only telehealth visits are not sufficient for initiating a Schedule IV controlled substance under Ryan Haight standards. Video capability is required for the initial prescribing encounter. Follow-up visits after the initial video consultation may be handled via secure messaging or phone under certain Vermont telehealth provider policies, but prescribers must document clinical judgment each time a refill is issued.

Dayvigo Pharmacy Access in Vermont: Retail, Mail-Order, and 503A

Vermont has approximately 170 licensed retail pharmacy locations, including chains and independent pharmacies. Dayvigo 5 mg and 10 mg tablets are stocked at major chains statewide. Independent pharmacies in rural Vermont counties such as Essex, Orleans, and Caledonia may need 24 to 48 hours to special-order the medication if stock is low; calling ahead is practical.

Mail-order pharmacies licensed by the Vermont Board of Pharmacy (including Walgreens Mail Service, CVS Caremark, and Express Scripts) may ship lemborexant to Vermont addresses. Because it is a Schedule IV controlled substance, federal law requires a written or EPCS prescription; verbal telephone orders are not permitted for Schedule IV drugs 12.

503A compounding pharmacies licensed in Vermont may compound lemborexant formulations for patients with a valid, patient-specific prescription. This option is relevant for patients who require a dose form not commercially available, such as a liquid suspension for dysphagia. Vermont 503A pharmacies must compound under USP 795 guidelines and may not produce compounded lemborexant for office stock or in anticipation of prescriptions 13.

GoodRx coupons reduce the out-of-pocket cost of Dayvigo to approximately $250 to $320 per 30-tablet supply at Vermont retail pharmacies as of early 2025, compared with a list price exceeding $400. The Eisai patient assistance program (EASI-Access) provides free or reduced-cost Dayvigo to uninsured or underinsured Vermont patients who meet income thresholds.

Dosing and How to Take Lemborexant Correctly

The FDA-approved starting dose of lemborexant is 5 mg taken orally once per night, immediately before going to bed, with at least 7 hours remaining before the planned wake time 1. The dose may be increased to 10 mg based on clinical response and tolerability. The 10 mg dose is not recommended for patients with moderate hepatic impairment or for patients taking moderate CYP3A inhibitors such as fluconazole.

Taking lemborexant with or shortly after a high-fat meal delays the time to peak plasma concentration (Tmax) by approximately 2 hours and reduces maximum concentration, which may slow sleep onset. Patients are instructed to take the tablet on an empty stomach or after a light snack 1.

Elderly patients (age 65 and older) respond well to the 5 mg dose. SUNRISE-2 included a prespecified elderly subgroup analysis showing statistically significant improvements in both sleep onset and sleep maintenance at 5 mg without an increase in falls or next-morning sedation compared with placebo 3. Vermont's older adult population, which comprises approximately 20% of the state's residents per 2020 Census data, may particularly benefit from lemborexant's favorable fall-risk profile relative to benzodiazepine receptor agonists 14.

Do not take a second dose on the same night if you wake up and feel you cannot return to sleep. The drug's half-life is approximately 17 to 19 hours; a second dose would produce dangerously elevated plasma concentrations by morning.

Transferring an Existing Dayvigo Prescription to Vermont

Patients relocating to Vermont from another state sometimes ask whether they can transfer their Dayvigo prescription. For Schedule IV controlled substances, federal law (21 CFR 1306.25) permits a one-time transfer of an original valid prescription between pharmacies if the prescription has not been previously transferred 12. Practically, this means you can transfer a Dayvigo prescription from an out-of-state pharmacy to a Vermont pharmacy one time. After that transfer, subsequent refills must be dispensed by the receiving Vermont pharmacy.

Patients who had a lemborexant prescription written by an out-of-state prescriber should note that Vermont pharmacies can fill that prescription as long as it was written by a licensed prescriber in the originating state and does not exceed a 30-day supply per fill. Once you establish Vermont residency and need a new prescription, you must see a Vermont-licensed prescriber (in-person or telehealth) who holds a valid Vermont DEA registration.

Transferring care to a new prescriber in Vermont is straightforward. Request records from your previous prescriber showing your diagnosis and treatment history, bring a medication list to your first Vermont visit, and inform the new prescriber of your current dose and any prior adverse effects.

Safety Considerations Vermont Clinicians Emphasize

The FDA issued a Boxed Warning for Dayvigo in 2020 covering complex sleep behaviors, including sleep-walking, sleep-driving, and sleep-cooking, some of which resulted in serious injuries and deaths when patients were not fully awake 1. Dayvigo should be discontinued immediately if a patient reports any complex sleep behavior episode.

Next-morning impairment is a specific concern. The FDA label includes data from a simulated driving study showing that lemborexant 10 mg produced statistically significant impairment at 9 hours post-dose on night 1 (P<0.05), though the 5 mg dose did not show significant driving impairment at that time point 1. Vermont patients who must drive in the early morning hours are advised to start with 5 mg and evaluate their alertness carefully before operating a vehicle.

Alcohol consumption within 4 hours of taking lemborexant substantially increases CNS depression. Vermont clinicians routinely counsel patients on this interaction at initiation and document the counseling in the medical record.

Abrupt discontinuation does not produce a clinically significant withdrawal syndrome based on SUNRISE-2 discontinuation data 3. Rebound insomnia after stopping lemborexant was mild and transient, which distinguishes it from benzodiazepines and most Z-drugs. Patients can stop lemborexant without a taper, though gradual dose reduction is optional if preferred.

The AASM guideline specifically notes: "We recommend dual orexin receptor antagonists (DORAs) as first-line pharmacologic therapy for chronic insomnia disorder, given their favorable efficacy and safety profile compared with GABA-A receptor agonists" 4. Vermont prescribers citing this guideline in PA submissions often receive faster approvals from commercial insurers.